GB0129007D0 - Adjuvanted antigenic meningococcal compositions - Google Patents
Adjuvanted antigenic meningococcal compositionsInfo
- Publication number
- GB0129007D0 GB0129007D0 GBGB0129007.1A GB0129007A GB0129007D0 GB 0129007 D0 GB0129007 D0 GB 0129007D0 GB 0129007 A GB0129007 A GB 0129007A GB 0129007 D0 GB0129007 D0 GB 0129007D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- adjuvanted
- compositions
- meningococcal compositions
- adjuvanted antigenic
- antigenic meningococcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000890 antigenic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129007.1A GB0129007D0 (en) | 2001-12-04 | 2001-12-04 | Adjuvanted antigenic meningococcal compositions |
| JP2003548874A JP4414226B2 (ja) | 2001-12-04 | 2002-12-04 | アジュバント化された抗原性髄膜炎菌性組成物 |
| AU2002353417A AU2002353417A1 (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| CA2468935A CA2468935C (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| AT02788442T ATE485055T1 (de) | 2001-12-04 | 2002-12-04 | Adjuvierte antigene meningokokkenzusammensetzungen |
| PCT/IB2002/005662 WO2003047619A2 (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| US10/497,709 US20060008476A1 (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| EP02788442A EP1448230B1 (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| APAP/P/2004/003074A AP2004003074A0 (en) | 2001-12-04 | 2002-12-04 | Adjuvanted antigenic meningococcal compositions |
| DE60238075T DE60238075D1 (de) | 2001-12-04 | 2002-12-04 | Adjuvierte antigene meningokokkenzusammensetzungen |
| JP2009096521A JP2009155344A (ja) | 2001-12-04 | 2009-04-10 | アジュバント化された抗原性髄膜炎菌性組成物 |
| US12/787,366 US20100233205A1 (en) | 2001-12-04 | 2010-05-25 | Adjuvanted antigenic meningococcal compositions |
| CY20111100056T CY1111114T1 (el) | 2001-12-04 | 2011-01-18 | Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129007.1A GB0129007D0 (en) | 2001-12-04 | 2001-12-04 | Adjuvanted antigenic meningococcal compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0129007D0 true GB0129007D0 (en) | 2002-01-23 |
Family
ID=9926977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0129007.1A Ceased GB0129007D0 (en) | 2001-12-04 | 2001-12-04 | Adjuvanted antigenic meningococcal compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20060008476A1 (enExample) |
| EP (1) | EP1448230B1 (enExample) |
| JP (2) | JP4414226B2 (enExample) |
| AP (1) | AP2004003074A0 (enExample) |
| AT (1) | ATE485055T1 (enExample) |
| AU (1) | AU2002353417A1 (enExample) |
| CA (1) | CA2468935C (enExample) |
| CY (1) | CY1111114T1 (enExample) |
| DE (1) | DE60238075D1 (enExample) |
| GB (1) | GB0129007D0 (enExample) |
| WO (1) | WO2003047619A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| JP4763210B2 (ja) * | 2000-02-28 | 2011-08-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリアのタンパク質の異種発現 |
| DE60234695D1 (de) * | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| AU2003239744B2 (en) * | 2002-05-14 | 2008-07-03 | Novartis Vaccines And Diagnostics S.R.L. | Mucosal combination vaccines for bacterial meningitis |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| ES2397923T3 (es) * | 2003-10-02 | 2013-03-12 | Novartis Ag | Vacunas líquidas para múltiples serogrupos meningocócicos |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| NZ595234A (en) | 2009-03-24 | 2013-12-20 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
| DK2608805T4 (da) | 2010-08-23 | 2025-06-30 | Wyeth Llc | STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER |
| RU2546873C2 (ru) | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
| EP2635593B1 (en) * | 2010-11-05 | 2016-09-14 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Vaccines for preventing meningococcal infections |
| GB201102090D0 (en) * | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| PE20190458A1 (es) | 2012-03-09 | 2019-04-01 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas |
| CA2875391A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| MX391027B (es) | 2015-02-19 | 2025-03-21 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| WO2020124159A1 (en) * | 2018-12-21 | 2020-06-25 | Griffith University | Compositions, methods and uses for eliciting an immune response |
| CN115605222A (zh) | 2019-09-27 | 2023-01-13 | 辉瑞公司(Us) | 脑膜炎奈瑟氏菌组合物及其方法 |
| US20220348645A1 (en) * | 2019-10-01 | 2022-11-03 | Beth Israel Deaconess Medical Center, Inc. | Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| JP4472866B2 (ja) * | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
| GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| SG152917A1 (en) * | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| MXPA01003228A (es) * | 1998-09-30 | 2003-06-24 | American Cyanamid Co | Holotoxina de colera mutante como un coadyuvante. |
| US7384640B1 (en) * | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
| AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
-
2001
- 2001-12-04 GB GBGB0129007.1A patent/GB0129007D0/en not_active Ceased
-
2002
- 2002-12-04 WO PCT/IB2002/005662 patent/WO2003047619A2/en not_active Ceased
- 2002-12-04 AT AT02788442T patent/ATE485055T1/de not_active IP Right Cessation
- 2002-12-04 US US10/497,709 patent/US20060008476A1/en not_active Abandoned
- 2002-12-04 JP JP2003548874A patent/JP4414226B2/ja not_active Expired - Fee Related
- 2002-12-04 EP EP02788442A patent/EP1448230B1/en not_active Expired - Lifetime
- 2002-12-04 DE DE60238075T patent/DE60238075D1/de not_active Expired - Lifetime
- 2002-12-04 AU AU2002353417A patent/AU2002353417A1/en not_active Abandoned
- 2002-12-04 AP APAP/P/2004/003074A patent/AP2004003074A0/en unknown
- 2002-12-04 CA CA2468935A patent/CA2468935C/en not_active Expired - Fee Related
-
2009
- 2009-04-10 JP JP2009096521A patent/JP2009155344A/ja not_active Withdrawn
-
2010
- 2010-05-25 US US12/787,366 patent/US20100233205A1/en not_active Abandoned
-
2011
- 2011-01-18 CY CY20111100056T patent/CY1111114T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002353417A1 (en) | 2003-06-17 |
| CY1111114T1 (el) | 2015-06-11 |
| JP2009155344A (ja) | 2009-07-16 |
| CA2468935C (en) | 2013-02-05 |
| US20100233205A1 (en) | 2010-09-16 |
| ATE485055T1 (de) | 2010-11-15 |
| AP2004003074A0 (en) | 2004-06-30 |
| WO2003047619A3 (en) | 2003-10-23 |
| DE60238075D1 (de) | 2010-12-02 |
| CA2468935A1 (en) | 2003-06-12 |
| JP4414226B2 (ja) | 2010-02-10 |
| EP1448230B1 (en) | 2010-10-20 |
| JP2005511662A (ja) | 2005-04-28 |
| EP1448230A2 (en) | 2004-08-25 |
| US20060008476A1 (en) | 2006-01-12 |
| WO2003047619A2 (en) | 2003-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0129007D0 (en) | Adjuvanted antigenic meningococcal compositions | |
| HUP0301413A3 (en) | Vaccine compositions | |
| IL227966A0 (en) | Vaccination kit | |
| GB0103170D0 (en) | Vaccine composition | |
| GB0103171D0 (en) | Vaccine composition | |
| HUP0302117A3 (en) | Vaccine composition | |
| IL188834A0 (en) | Novel vaccine composition | |
| GB0020089D0 (en) | Vaccine Composition | |
| GB0024200D0 (en) | Component vaccine | |
| GB2360210B (en) | Sublingual vaccine formulation | |
| GB0306611D0 (en) | Novel vaccine | |
| HUP0303942A3 (en) | Novel vaccine composition | |
| GB0121171D0 (en) | Vaccine | |
| GB0126266D0 (en) | Anthrax antigenic compositions | |
| ZA200401211B (en) | Antigenic compositions | |
| AU2001267541A1 (en) | Vaccine composition | |
| GB0027433D0 (en) | Vaccine component | |
| GB0006770D0 (en) | Vaccine composition | |
| GB0101138D0 (en) | Vaccine composition | |
| GB0108363D0 (en) | Vaccine composition | |
| GB0100512D0 (en) | Vaccine composition | |
| HK1066178A (en) | Antigenic compositions | |
| GB0016686D0 (en) | Novel vaccine | |
| GB0104538D0 (en) | Novel Vaccine | |
| GB0107511D0 (en) | Novel vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |